SEC Form 4 filed by Beshar Luke M

$TRIL
Major Pharmaceuticals
Health Care
Get the next $TRIL alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
BESHAR LUKE M

(Last) (First) (Middle)
C/O TRILLIUM THERAPEUTICS INC.
2488 DUNWIN DRIVE

(Street)
MISSISSAUGA A6 L5L 1J9

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Trillium Therapeutics Inc. [ TRIL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2021
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $12.03 11/17/2021 D 40,000 (2) 12/23/2030 Common Shares 40,000 $0 0 D
Stock Option (Right to Buy) $14.93(1) 11/17/2021 D 6,666 (2) 03/06/2024 Common Shares 6,666 $0 0 D
Deferred Share Unit (2) 11/17/2021 D 547,656.26 (2) (3) Common Shares 547,656.26 (2) 0 D
Explanation of Responses:
1. The exercise price of these options is $18.90 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD
2. On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.
3. N/A
/s/ James Parsons, Attorney-in-Fact 11/19/2021
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $TRIL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TRIL

DatePrice TargetRatingAnalyst
11/17/2021Buy → Hold
The Benchmark Company
11/17/2021Buy → Hold
Benchmark
8/24/2021$21.00 → $18.50Buy → Hold
Craig-Hallum
8/24/2021Market Outperform → Market Perform
JMP Securities
8/23/2021$22.00 → $18.50Buy → Neutral
HC Wainwright & Co.
More analyst ratings

$TRIL
Press Releases

Fastest customizable press release news feed in the world

See more
  • Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors

    Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Additionally, James T. Parsons was elected to the Oncolytics Biotech Board of Directors. Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM. Mr. Parsons commented, "Oncolytics' clini

    $DMAC
    $ONCY
    $TRIL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
  • Trillium Therapeutics Receives Final Court Order Approving Arrangement

    CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce that it has received a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the "Arrangement") with PF Argentum ULC ("PF Argentum"), a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE:PFE) ("Pfizer"). Pursuant to the Arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium other than Trillium securities owned by Pfizer and its affiliates

    $PFE
    $TRIL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
  • Frazier Healthcare Partners Closes Oversubscribed $830 Million Life Sciences Public Fund

    Frazier Healthcare Partners announced today the closing of Frazier Life Sciences Public Fund, L.P., exceeding its target and closing on nearly $830 million in capital commitments in an oversubscribed fundraise. Led by Managing Partner Albert Cha, General Partner and Portfolio Manager Jamie Brush, and Managing Partners Patrick Heron and James Topper, Frazier Life Sciences Public Fund is a long-only fund investing in small- and mid-cap public biotech companies. Frazier Life Sciences Public Fund marks Frazier's first dedicated public life sciences fund, bringing the firm's total committed capital raised since inception to over $7.1 billion. "We are thrilled to announce the launch of our publ

    $RCKT
    $TBIO
    $TRIL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$TRIL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TRIL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TRIL
SEC Filings

See more

$TRIL
Leadership Updates

Live Leadership Updates

See more
  • Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors

    Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Additionally, James T. Parsons was elected to the Oncolytics Biotech Board of Directors. Leonard (Leon) Kruimer did not stand for re-election as a director at the AGM. Mr. Parsons commented, "Oncolytics' clini

    $DMAC
    $ONCY
    $TRIL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
  • Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of Directors

    CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Catherine Mackey, Ph.D., to its Board of Directors, effective immediately. "We are excited to welcome Dr. Mackey to our board of directors," said Paolo Pucci, Lead Director of Trillium.  "Her significant executive experience and expertise leading research and development organizations will be invaluable as Trillium advances its two lead product candidates into a Phase 1b/2 program." Dr. Mackey has more t

    $TRIL
    Major Pharmaceuticals
    Health Care
  • Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team

    MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate. Aditya Kohli, Ph.D., joined the Frazier Life Sciences team in 2016 and focuses on company creation. He co-founded Phathom Pharmaceuticals (NASDAQ: PHAT) and Scout Bio, and helped launch Passage Bio (NASDAQ: PASG). Dr. Kohli serves as the Chief Business Officer of Phathom Pharmaceuticals and as a member of the board of directors for Scout Bio. Anna Chen, Ph.D., joined Frazier in 2018 and focuses on evaluating investment opportunities and creating new

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

$TRIL
Financials

Live finance-specific insights

See more
  • Pfizer to Acquire Trillium Therapeutics Inc.

    Proposed acquisition strengthens Pfizer's category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Expands innovative pipeline, potentially enhancing growth in 2026-2030 and beyond Pfizer to host analyst and investor call at 10:00 a.m. ET today with Pfizer Oncology executives Pfizer Inc. (NYSE:PFE) and Trillium Therapeutics Inc. (TSX:TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire al

    $PFE
    $TRIL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

$TRIL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more